Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

HIV/AIDS vaccines: 2007.

¹Yerkes National Primate Research Center, Emory Vaccine Center, Emory University School of Medicine, Emory University, Atlanta, Georgia, USA. hrobins@rmy.emory.edu

Clinical Pharmacology and Therapeutics

|November 1, 2007

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

A case of paramyotonia congenita in pregnancy.

Obstetric medicine·2020

Same author

Economic background to public health during the war.

Canadian journal of public health = Revue canadienne de sante publique·2010

Same author

Rates of stillbirths in Canada.

Canadian journal of public health = Revue canadienne de sante publique·2010

Same author

Nucleic acid immunizations.

Current protocols in immunology·2008

Same author

DNA vaccines: a review of developments.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2007

Same author

Excellent safety and tolerability of the human immunodeficiency virus type 1 pGA2/JS2 plasmid DNA priming vector vaccine in HIV type 1 uninfected adults.

AIDS research and human retroviruses·2006

Same journal

Symposium Report: Stakeholders' Perspectives on Phase 1 Trials in Japanese Prior to Multi-Regional Clinical Trials and Future Pathways.

Clinical pharmacology and therapeutics·2026

Same journal

Resolving CYP2D6 Structural Complexity with Long-Read Sequencing: Implications for Tamoxifen Precision Dosing in Thai Breast Cancer Patients.

Clinical pharmacology and therapeutics·2026

Same journal

Identification of a Functional CYP2C8 Variant Allele that Alters Splicing, Reduces Protein Expression, and Increases Drug Exposure.

Clinical pharmacology and therapeutics·2026

Same journal

Risk of Hyperkalemia in Patients with Heart Failure Treated with Spironolactone in Combination with Sacubitril/Valsartan vs. Renin-Angiotensin System Inhibitors.

Clinical pharmacology and therapeutics·2026

Same journal

Composite Endpoints in Contemporary Cardiovascular Trials: Trends in Phase 3 Trials and Key Issues in Regulatory Review.

Clinical pharmacology and therapeutics·2026

Same journal

Patient-Specific Determinants of Response to BCMA- and GPRC5D-Targeted CAR T-Cell Therapy in Multiple Myeloma: A QSP Analysis of Clinical Trial and Real-World Data.

Clinical pharmacology and therapeutics·2026

See all related articles

Developing an effective HIV/AIDS vaccine remains challenging. However, novel approaches like viral vectors and DNA vaccines show promise in controlling the virus in animal models by eliciting T cell responses.

Area of Science:

Immunology
Vaccinology
Virology

Background:

Classical vaccine development strategies have faced significant hurdles in creating an effective HIV/AIDS vaccine.
The slow progress necessitates exploring innovative approaches to combat Human Immunodeficiency Virus (HIV) and Acquired Immunodeficiency Syndrome (AIDS).

Purpose of the Study:

To review novel vaccine development strategies for HIV/AIDS.
To highlight vaccines utilizing recombinant viral vectors, DNA vaccines, and heterologous prime/boost regimens.
To summarize the progress of six vaccines currently in human trials.

Main Methods:

Review of emerging vaccine technologies, including recombinant viral vectors and DNA vaccines.
Analysis of heterologous prime/boost immunization strategies.

Related Experiment Videos

Synopsis of clinical trial data for advanced HIV/AIDS vaccine candidates.

Main Results:

New vaccine approaches demonstrate efficacy in controlling virulent immunodeficiency virus challenges in non-human primate models.
These novel vaccines induce T cell responses crucial for recognizing and eliminating virus-infected cells.
Six vaccine candidates are progressing through human clinical trials.

Conclusions:

Innovative vaccine strategies, particularly those employing viral vectors and DNA, offer a promising path forward for HIV/AIDS prevention.
The induction of robust T cell immunity is a key mechanism for controlling HIV.
Advancements in vaccine technology are translating into clinical development, offering hope for an effective HIV/AIDS vaccine.